154 related articles for article (PubMed ID: 31278877)
1. FF-10832 enables long survival via effective gemcitabine accumulation in a lethal murine peritoneal dissemination model.
Higuchi T; Yokobori T; Takahashi R; Naito T; Kitahara H; Matsumoto T; Kakinuma C; Hagiwara S; Kuwano H; Shirabe K; Asao T
Cancer Sci; 2019 Sep; 110(9):2933-2940. PubMed ID: 31278877
[TBL] [Abstract][Full Text] [Related]
2. A Liposomal Gemcitabine, FF-10832, Improves Plasma Stability, Tumor Targeting, and Antitumor Efficacy of Gemcitabine in Pancreatic Cancer Xenograft Models.
Matsumoto T; Komori T; Yoshino Y; Ioroi T; Kitahashi T; Kitahara H; Ono K; Higuchi T; Sakabe M; Kori H; Kano M; Hori R; Kato Y; Hagiwara S
Pharm Res; 2021 Jun; 38(6):1093-1106. PubMed ID: 33961188
[TBL] [Abstract][Full Text] [Related]
3. Biodistribution and pharmacokinetics of 188Re-liposomes and their comparative therapeutic efficacy with 5-fluorouracil in C26 colonic peritoneal carcinomatosis mice.
Tsai CC; Chang CH; Chen LC; Chang YJ; Lan KL; Wu YH; Hsu CW; Liu IH; Ho CL; Lee WC; Ni HC; Chang TJ; Ting G; Lee TW
Int J Nanomedicine; 2011; 6():2607-19. PubMed ID: 22114492
[TBL] [Abstract][Full Text] [Related]
4. Tumor-specific delivery of gemcitabine with activatable liposomes.
Tucci ST; Kheirolomoom A; Ingham ES; Mahakian LM; Tam SM; Foiret J; Hubbard NE; Borowsky AD; Baikoghli M; Cheng RH; Ferrara KW
J Control Release; 2019 Sep; 309():277-288. PubMed ID: 31301340
[TBL] [Abstract][Full Text] [Related]
5. A phase I pharmacokinetic study of hypoxic abdominal stop-flow perfusion with gemcitabine in patients with advanced pancreatic cancer and refractory malignant ascites.
Kuemmerle A; Decosterd LA; Buclin T; Liénard D; Stupp R; Chassot PG; Mosimann F; Lejeune F
Cancer Chemother Pharmacol; 2009 Jan; 63(2):331-41. PubMed ID: 18587581
[TBL] [Abstract][Full Text] [Related]
6. Phase I trial of intraperitoneal gemcitabine in the treatment of advanced malignancies primarily confined to the peritoneal cavity.
Morgan RJ; Synold TW; Xi B; Lim D; Shibata S; Margolin K; Schwarz RE; Leong L; Somlo G; Twardowski P; Yen Y; Chow W; Tetef M; Lin P; Paz B; Koczywas M; Wagman L; Chu D; Frankel P; Stalter S; Doroshow JH
Clin Cancer Res; 2007 Feb; 13(4):1232-7. PubMed ID: 17317834
[TBL] [Abstract][Full Text] [Related]
7. Gemcitabine suppresses malignant ascites of human pancreatic cancer: correlation with VEGF expression in ascites.
Kuwahara K; Sasaki T; Kobayashi K; Noma B; Serikawa M; Iiboshi T; Miyata H; Kuwada Y; Murakami M; Yamasaki S; Kariya K; Morinaka K; Chayama K
Oncol Rep; 2004 Jan; 11(1):73-80. PubMed ID: 14654905
[TBL] [Abstract][Full Text] [Related]
8. Intraoperative and early postoperative chemotherapy into the abdominal cavity using gemcitabine may prevent postoperative occurence of peritoneal carcinomatosis.
Ridwelski K; Meyer F; Hribaschek A; Kasper U; Lippert H
J Surg Oncol; 2002 Jan; 79(1):10-6. PubMed ID: 11754372
[TBL] [Abstract][Full Text] [Related]
9. Weekly Paclitaxel after failure of gemcitabine in pancreatic cancer patients with malignant ascites: a retrospective study.
Shukuya T; Yasui H; Boku N; Onozawa Y; Fukutomi A; Yamazaki K; Taku K; Kojima T; Machida N
Jpn J Clin Oncol; 2010 Dec; 40(12):1135-8. PubMed ID: 20656694
[TBL] [Abstract][Full Text] [Related]
10. Antitumor activity and pharmacokinetics of liposomes containing lipophilic gemcitabine prodrugs.
Brusa P; Immordino ML; Rocco F; Cattel L
Anticancer Res; 2007; 27(1A):195-9. PubMed ID: 17352232
[TBL] [Abstract][Full Text] [Related]
11. PEGylated liposome IHL-305 markedly improved the survival of ovarian cancer peritoneal metastasis in mouse.
Konishi H; Takagi A; Kurita A; Kaneda N; Matsuzaki T
BMC Cancer; 2012 Oct; 12():462. PubMed ID: 23046546
[TBL] [Abstract][Full Text] [Related]
12. Preparation, characterization, cytotoxicity and pharmacokinetics of liposomes containing lipophilic gemcitabine prodrugs.
Immordino ML; Brusa P; Rocco F; Arpicco S; Ceruti M; Cattel L
J Control Release; 2004 Dec; 100(3):331-46. PubMed ID: 15567500
[TBL] [Abstract][Full Text] [Related]
13. Comparative pharmacokinetics and metabolic pathway of gemcitabine during intravenous and intra-arterial delivery in unresectable pancreatic cancer patients.
Shamseddine AI; Khalifeh MJ; Mourad FH; Chehal AA; Al-Kutoubi A; Abbas J; Habbal MZ; Malaeb LA; Bikhazi AB
Clin Pharmacokinet; 2005; 44(9):957-67. PubMed ID: 16122282
[TBL] [Abstract][Full Text] [Related]
14. Pressure-enabled delivery of gemcitabine in an orthotopic pancreatic cancer mouse model.
Shankara Narayanan JS; Vicente DA; Ray P; Chai LF; Erdem S; Carr MJ; Capacio BA; Cox BF; Jaroch DB; Katz SC; White RR
Surgery; 2020 Sep; 168(3):448-456. PubMed ID: 32620306
[TBL] [Abstract][Full Text] [Related]
15. Antitumor activity of prolonged as compared with bolus administration of 2',2'-difluorodeoxycytidine in vivo against murine colon tumors.
Veerman G; Ruiz van Haperen VW; Vermorken JB; Noordhuis P; Braakhuis BJ; Pinedo HM; Peters GJ
Cancer Chemother Pharmacol; 1996; 38(4):335-42. PubMed ID: 8674156
[TBL] [Abstract][Full Text] [Related]
16. Long-circulatory nanoparticles for gemcitabine delivery: Development and investigation of pharmacokinetics and in-vivo anticancer efficacy.
Khare V; Singh A; Mahajan G; Alam N; Kour S; Gupta M; Kumar A; Singh G; Singh SK; Saxena AK; Mondhe DM; Gupta PN
Eur J Pharm Sci; 2016 Sep; 92():183-93. PubMed ID: 27404580
[TBL] [Abstract][Full Text] [Related]
17. Impact of carrier solutions on pharmacokinetics of intraperitoneal chemotherapy.
Pestieau SR; Schnake KJ; Stuart OA; Sugarbaker PH
Cancer Chemother Pharmacol; 2001 Mar; 47(3):269-76. PubMed ID: 11320672
[TBL] [Abstract][Full Text] [Related]
18. [A Case Report of Curative Surgery for Pancreatic Ductal Adenocarcinoma with Peritoneal Dissemination after Gemcitabine Chemotherapy].
Ichikawa Y; Yamada D; Eguchi H; Iwagami Y; Noda T; Asaoka T; Wada H; Kawamoto K; Gotoh K; Kobayashi S; Tatsumi M; Takeyari M; Mori M; Doki Y
Gan To Kagaku Ryoho; 2017 Nov; 44(12):2014-2016. PubMed ID: 29394852
[TBL] [Abstract][Full Text] [Related]
19. Gemcitabine-loaded RGD modified liposome for ovarian cancer: preparation, characterization and pharmacodynamic studies.
Tang Z; Feng W; Yang Y; Wang Q
Drug Des Devel Ther; 2019; 13():3281-3290. PubMed ID: 31571830
[TBL] [Abstract][Full Text] [Related]
20. The utility of hyperthermic intra-abdominal chemotherapy with gemcitabine for the inhibition of tumor progression in an experimental model of pancreatic peritoneal carcinomatosis, in relation to their behavior with pancreatic cancer stem cells CD133+ CXCR4.
García-Santos EP; Padilla-Valverde D; Villarejo-Campos P; Murillo-Lázaro C; Fernández-Grande E; Palomino-Muñoz T; Rodríguez-Martínez M; Amo-Salas M; Nuñez-Guerrero P; Sánchez-García S; Puerto-Puerto A; Martín-Fernández J
Pancreatology; 2016; 16(4):632-9. PubMed ID: 27289344
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
